Terazosin Capsule
Product Images NDC 71610-715

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 71610-715). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 1 mg (71610 0715 60)

Label for Terazosin USP 1 mg capsules, showing packaging details for 90 capsules. The label includes storage instructions, manufacturer Jubliant Cadista Pharmaceuticals Inc., and repackager Aphena Pharma Solutions - Tennessee, LLC. The NDC number 71610-0715-60 is visible along with batch and expiration info placeholders.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Terazosin Hydrochloride Chemical Structure (Terazosin Hydrochloride Capsules 1)

Chemical structure diagram of Terazosin Hydrochloride, showing its molecular framework with aromatic rings, nitrogen atoms, and functional groups including methoxy, amine, and carbamate moieties.*

FDA Label Image

Figure 1 (Terazosin Hydrochloride Capsules 2)

This image shows two line graphs comparing placebo and Terazosin groups over three months. The left graph illustrates mean change in total symptom score from baseline, with Terazosin showing a greater decrease. The right graph shows mean increase in peak flow rate from baseline (mL/sec), with Terazosin demonstrating a higher increase compared to placebo.*

FDA Label Image

Figure 2 (Terazosin Hydrochloride Capsules 3)

A line chart showing mean change from baseline over a 30-month period with monthly intervals marked. The Y-axis represents the mean change value ranging from 0 to -7, while the X-axis shows time in months from 0 to 30. Data points depict a decreasing trend that levels off over time, with some points marked by asterisks to denote significance.*

FDA Label Image

Figure 3 (Terazosin Hydrochloride Capsules 4)

A line graph showing mean change from baseline over a 30-month period with data points at monthly intervals. The y-axis represents the mean change from baseline, and a notable upward trend is indicated by dots and asterisks marking significance at various months.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.